Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v.   - paliperidono palmitatas - Šizofrenija - psicholeptikai - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bijon medica, uab - pantoprazolas - skrandyje neirios tabletės - 40 mg - pantoprazole

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bijon medica, uab - pantoprazolas - skrandyje neirios tabletės - 20 mg - pantoprazole

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

centrient pharmaceuticals netherlands b.v. - amoksicilinas/klavulano rūgštis - milteliai geriamajai suspensijai - 200 mg/28,5 mg/5 ml - amoxicillin and beta-lactamase inhibitor

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka d.d., novo mesto (slovėnija) - kramtomosios tabletės - veikliųjų medžiagų: milbemicino oksimo 12,5 mg, prazikvantelio 125,0 mg; - Šunims gydyti, esant mišriam užsikrėtimui toliau išvardytomis suaugusių cestodų ir nematodų rūšimis: - cestodai: dipylidium caninum, taenia spp., echinococcus spp., mesocestoides spp.. - nematodai: ancylostoma caninum, toxocara canis, toxascaris leonina, trichuris vulpis, crenosoma vulpis (užsikrėtimo lygiui mažinti). angiostrongylus vasorum (užsikrėtimo lygiui mažinti užsikrėtus nesubrendusiais suaugusiais (l5) ir suaugusiais parazitais; specifinės gydymo ir ligos profilaktikos schemos pateiktos 4.9 p. „dozės ir naudojimo būdas“). thelazia callipaeda (specifinė gydymo schema pateikta 4.9 p. „dozės ir naudojimo būdas“). be to, šį vaistą galima naudoti širdies kirmėlių ligos (dirofilaria immitis) profilaktikai, jei tuo pat metu reikalingas gydymas nuo cestodų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lv system service sia - sorafenibas - plėvele dengtos tabletės - 200 mg - sorafenib